TWI884745B - 甲狀腺素受體β促效劑化合物 - Google Patents

甲狀腺素受體β促效劑化合物 Download PDF

Info

Publication number
TWI884745B
TWI884745B TW113111231A TW113111231A TWI884745B TW I884745 B TWI884745 B TW I884745B TW 113111231 A TW113111231 A TW 113111231A TW 113111231 A TW113111231 A TW 113111231A TW I884745 B TWI884745 B TW I884745B
Authority
TW
Taiwan
Prior art keywords
substituted
group
alkyl
μmol
cycloalkyl
Prior art date
Application number
TW113111231A
Other languages
English (en)
Chinese (zh)
Other versions
TW202430520A (zh
Inventor
索爾斯坦 A 科許柏格
朗道爾 海克
英姿 徐
F 安東尼 羅梅洛
Original Assignee
美商拓臻股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商拓臻股份有限公司 filed Critical 美商拓臻股份有限公司
Publication of TW202430520A publication Critical patent/TW202430520A/zh
Application granted granted Critical
Publication of TWI884745B publication Critical patent/TWI884745B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW113111231A 2018-10-12 2019-10-09 甲狀腺素受體β促效劑化合物 TWI884745B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745195P 2018-10-12 2018-10-12
US62/745,195 2018-10-12

Publications (2)

Publication Number Publication Date
TW202430520A TW202430520A (zh) 2024-08-01
TWI884745B true TWI884745B (zh) 2025-05-21

Family

ID=70161488

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113111231A TWI884745B (zh) 2018-10-12 2019-10-09 甲狀腺素受體β促效劑化合物
TW108136747A TWI840423B (zh) 2018-10-12 2019-10-09 甲狀腺素受體β促效劑化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108136747A TWI840423B (zh) 2018-10-12 2019-10-09 甲狀腺素受體β促效劑化合物

Country Status (9)

Country Link
US (2) US11203587B2 (cg-RX-API-DMAC7.html)
EP (1) EP3863635A4 (cg-RX-API-DMAC7.html)
JP (2) JP7595004B2 (cg-RX-API-DMAC7.html)
CN (1) CN112839655B (cg-RX-API-DMAC7.html)
AR (1) AR116694A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019357618B2 (cg-RX-API-DMAC7.html)
MA (1) MA53868A (cg-RX-API-DMAC7.html)
TW (2) TWI884745B (cg-RX-API-DMAC7.html)
WO (1) WO2020077123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
WO2021244582A1 (zh) * 2020-06-02 2021-12-09 成都康弘药业集团股份有限公司 新型甲状腺激素β受体激动剂
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
JP2024510935A (ja) * 2021-03-03 2024-03-12 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090005383A1 (en) * 2005-07-21 2009-01-01 Nancy-Ellen Haynes Thyroid hormone analogs
US20170334883A1 (en) * 2014-09-05 2017-11-23 Genentech, Inc. Therapeutic compounds and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
CA2473162A1 (en) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
FR2882750B1 (fr) * 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
FR2933979B1 (fr) 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
KR101396606B1 (ko) 2009-04-20 2014-05-16 미쓰비시 타나베 파마 코퍼레이션 신규 갑상선 호르몬 β 수용체 작동약
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
EA023521B1 (ru) * 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
WO2020041741A1 (en) 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN119552152A (zh) 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
WO2020239076A1 (zh) 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090005383A1 (en) * 2005-07-21 2009-01-01 Nancy-Ellen Haynes Thyroid hormone analogs
US20170334883A1 (en) * 2014-09-05 2017-11-23 Genentech, Inc. Therapeutic compounds and uses thereof

Also Published As

Publication number Publication date
CN112839655B (zh) 2025-11-25
MA53868A (fr) 2021-08-18
TW202430520A (zh) 2024-08-01
US20200115362A1 (en) 2020-04-16
EP3863635A1 (en) 2021-08-18
AU2019357618A1 (en) 2021-04-29
TW202027748A (zh) 2020-08-01
AR116694A1 (es) 2021-06-02
CN112839655A (zh) 2021-05-25
JP2022504620A (ja) 2022-01-13
JP2025041602A (ja) 2025-03-26
EP3863635A4 (en) 2022-06-15
AU2019357618B2 (en) 2025-04-24
WO2020077123A1 (en) 2020-04-16
TWI840423B (zh) 2024-05-01
US20220348561A1 (en) 2022-11-03
CA3114015A1 (en) 2020-04-16
JP7595004B2 (ja) 2024-12-05
US11203587B2 (en) 2021-12-21

Similar Documents

Publication Publication Date Title
TWI840423B (zh) 甲狀腺素受體β促效劑化合物
JP7846735B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
JP7646632B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
JP7611832B2 (ja) 特定の白血病を治療するための化合物
JP7187449B2 (ja) Ehmt2阻害剤としての置換された融合二環式または三環式複素環化合物
AU2009217201B2 (en) Nitrogen-containing bycyclic compounds active on chronic pain conditions
CA3212130A1 (en) Thyroid hormone receptor beta agonist compounds
JP5465716B2 (ja) Nk1受容体アンタゴニストとしての5−[5−[2−(3,5−ビス(トリフルオロメチル)フェニル)−2−メチルプロパノイルメチルアミノ]−4−(4−フルオロ−2−メチルフェニル)]−2−ピリジニル−2−アルキル−プロリンアミド
WO2011054773A1 (en) Novel lactam compounds
RU2804709C9 (ru) Соединения для лечения некоторых лейкозов